View article

The present work is the last of a three‐part study investigating a panel of 30 systematically designed synthetic cannabinoid receptor agonists (SCRAs) including features such as the 4‐pentenyl tail and varying head groups including amides and esters of l‐valine (MMB, AB), l‐tert‐leucine (ADB), and l‐phenylalanine (APP), as well as adamantyl (A) and cumyl moieties (CUMYL). Here, we evaluated these SCRAs for their capacity to activate the human cannabinoid receptor 1 (CB₁) via indirect measurement of G protein recruitment. Furthermore, we comparatively evaluated the results obtained from three in vitro assays, based on the recruitment of β‐arrestin 2 (βarr2 assay) or Gα_i protein (mini‐Gα_i assay), or binding of [³⁵S]‐GTPγS. The observed efficacies (E_max) varied depending on the conducted assay. Statistical analysis suggests that the population means of the relative intrinsic activity (RA_i) significantly differ for …